Crofab market forecast points to faster growth in Asia-Pacific

Nov. 2, 2026
Crofab market forecast points to faster growth in Asia-Pacific
By AI, Created 14:00 UTC, Nov 02, 2026, AGP -

The Business Research Company says demand for Crofab is being lifted by rising snakebite cases, higher healthcare spending and expanding emergency care capacity. The market research firm says North America led in 2025, while Asia-Pacific is set to grow fastest over the forecast period.

Why it matters: - Crofab is a specialized antivenom used in emergency care for snakebite victims. - The market outlook points to sustained demand as more countries invest in snakebite treatment, rural healthcare and emergency response. - North America led the market in 2025, but Asia-Pacific is expected to be the fastest-growing region over the forecast period.

What happened: - The Business Research Company published a new Crofab market analysis on Nov. 2, 2026. - The report says the Crofab market is gaining traction as demand for effective snakebite treatment rises worldwide. - The company made the report available through a free sample request. - The full report is available online.

The details: - Crofab treats bites from pit vipers, including rattlesnakes, copperheads and cottonmouths. - The antivenom is given intravenously. - Crofab neutralizes venom toxins to reduce swelling, pain and organ damage. - Historical market growth has been driven by clinical effectiveness, established emergency protocols, greater exposure to outdoor environments, stronger hospital readiness and government support for antivenom availability. - Future growth is expected to come from wider access to emergency healthcare, better awareness of snakebite management, improved rural healthcare infrastructure, government funding for antivenom production and advances in biologic antitoxins. - The report highlights steady demand for snakebite antivenoms, stronger focus on envenomation treatment, expansion of trauma care facilities, better access to targeted antivenoms and greater awareness of rapid intervention. - Rising snakebite incidents are a key demand driver. - The report cites an October 2023 National Library of Medicine finding that Australia sees about 3,000 snakebite cases a year, with roughly 500 hospitalizations and about two deaths annually. - Higher healthcare spending is also supporting the market. - The UK Office for National Statistics reported a 5.6% increase in healthcare spending between 2022 and 2023, compared with 0.9% growth the prior year. - Growth in emergency care facilities is another market tailwind. - The Royal College of Emergency Medicine reported about 25.3 million Accident & Emergency visits in England in 2022/23, up 4% from the prior year. - The market analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The forecast suggests Crofab demand is tied less to a single product cycle and more to broader emergency-care readiness. - Faster growth in Asia-Pacific likely reflects a larger mix of snakebite exposure, healthcare expansion and unmet treatment need across the region. - The report leans on public health and system-level indicators, which points to a market shaped by infrastructure as much as by clinical demand.

What's next: - The company expects snakebite antivenom demand to remain steady across the forecast period. - Emergency envenomation treatment, trauma care expansion and targeted antivenom access are likely to stay central themes in the market. - Regional performance will continue to diverge, with North America retaining the largest share and Asia-Pacific expanding fastest. - The company also says its 2026 reports now include expanded strategic intelligence tools for market sizing and trend tracking.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Governance Reporter of Australia

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Governance Reporter of Australia

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.